studies

breast cancer - HR positive, taselisib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias objective responses (ORR)detailed resultsLORELEI, 2019 1.55 [1.00; 2.39] 1.55[1.00; 2.39]LORELEI, 201910%334NAnot evaluable pCR detailed resultsLORELEI, 2019 3.07 [0.32; 29.65] 3.07[0.32; 29.65]LORELEI, 201910%334NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-13 04:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 4,319,144,356,351,357,352,354,353,358,359 - treatments: 1377,1408,1378